AxoGen (NASDAQ:AXGN) Sets New 12-Month High – What’s Next?

AxoGen, Inc. (NASDAQ:AXGN)’s stock price reached a new 52-week high during mid-day trading on Monday . The company traded as high as $24.84 and last traded at $23.80, with a volume of 526 shares trading hands. The stock had previously closed at $23.57.

Wall Street Analysts Forecast Growth

AXGN has been the subject of a number of analyst reports. JMP Securities set a $34.00 price objective on shares of AxoGen in a research report on Thursday, October 30th. Raymond James Financial boosted their price target on shares of AxoGen from $20.00 to $27.00 and gave the stock an “outperform” rating in a research note on Thursday, October 30th. Wall Street Zen upgraded shares of AxoGen from a “hold” rating to a “buy” rating in a research report on Saturday, August 9th. Citizens Jmp boosted their target price on AxoGen from $26.00 to $34.00 and gave the stock a “market outperform” rating in a research report on Thursday, October 30th. Finally, HC Wainwright raised their price target on AxoGen from $25.00 to $26.00 and gave the company a “buy” rating in a report on Thursday, October 30th. Eight equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $28.86.

AxoGen Stock Up 1.1%

The firm has a market capitalization of $1.10 billion, a PE ratio of -473.10 and a beta of 1.09. The firm’s 50-day moving average is $17.89 and its 200 day moving average is $14.49. The company has a debt-to-equity ratio of 0.59, a quick ratio of 2.67 and a current ratio of 4.14.

AxoGen (NASDAQ:AXGN) last announced its quarterly earnings results on Wednesday, October 29th. The medical equipment provider reported $0.12 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.09 by $0.03. AxoGen had a negative net margin of 0.98% and a negative return on equity of 1.96%. The company had revenue of $60.08 million for the quarter, compared to the consensus estimate of $56.90 million. AxoGen has set its FY 2025 guidance at EPS. As a group, research analysts forecast that AxoGen, Inc. will post -0.29 earnings per share for the current fiscal year.

Insider Buying and Selling at AxoGen

In other news, Director William P. Mr. Burke sold 40,235 shares of the company’s stock in a transaction on Wednesday, October 29th. The stock was sold at an average price of $20.55, for a total value of $826,829.25. Following the sale, the director directly owned 100 shares in the company, valued at $2,055. This represents a 99.75% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders sold 110,782 shares of company stock valued at $2,292,049 over the last ninety days. Insiders own 2.78% of the company’s stock.

Institutional Investors Weigh In On AxoGen

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Future Financial Wealth Managment LLC acquired a new position in shares of AxoGen during the 3rd quarter valued at $27,000. State of Alaska Department of Revenue bought a new position in AxoGen during the third quarter worth $43,000. Tower Research Capital LLC TRC boosted its holdings in shares of AxoGen by 189.9% in the 2nd quarter. Tower Research Capital LLC TRC now owns 5,079 shares of the medical equipment provider’s stock valued at $55,000 after buying an additional 3,327 shares during the period. AlphaQuest LLC raised its position in shares of AxoGen by 882.2% during the 2nd quarter. AlphaQuest LLC now owns 6,276 shares of the medical equipment provider’s stock worth $68,000 after purchasing an additional 5,637 shares during the period. Finally, State of Wyoming bought a new stake in AxoGen in the second quarter valued at $69,000. 80.29% of the stock is currently owned by institutional investors and hedge funds.

About AxoGen

AxoGen, Inc, together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company’s products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries.